Supplementary Materials for
Consolidated Financial Results for
the 1st Quarter of Fiscal Year 2021. 12 (IFRS)
Chugai Pharmaceutical co., ltd.
Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
- Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
- Exchange rates used for each period are as follows.
QTR | (Yen) | |||||||||||
Actual* | Actual* | |||||||||||
FY2020 | FY2021 | |||||||||||
1-3 | 4-6 | 7-9 | 10-12 | 1-3 | 4-6 | 7-9 | 10-12 | |||||
QTR | QTR | QTR | QTR | QTR | QTR | QTR | QTR | |||||
CHF | 112.61 | 111.54 | 115.39 | 115.52 | 117.08 | |||||||
EUR | 120.19 | 118.35 | 124.06 | 124.51 | 127.65 | |||||||
USD | 109.02 | 107.53 | 106.16 | 104.50 | 105.83 | |||||||
SGD | 78.72 | 76.15 | 77.23 | 77.58 | 79.47 | |||||||
*Market average exchange rate | ||||||||||||
YTD | ||||||||||||
Actual* | Actual* | Actual* | Assumption | |||||||||
FY2019 | FY2020 | FY2021 | FY2021 | |||||||||
1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-12 | |||
Full-year | YTD | YTD | YTD | Full-year | YTD | YTD | YTD | Full-year | Full-year | |||
CHF | 109.72 | 112.61 | 112.07 | 113.14 | 113.72 | 117.08 | 116.00 | |||||
EUR | 122.08 | 120.19 | 119.27 | 120.80 | 121.69 | 127.65 | 126.00 | |||||
USD | 109.05 | 109.02 | 108.28 | 107.57 | 106.80 | 105.83 | 105.00 | |||||
SGD | 79.94 | 78.72 | 77.42 | 77.36 | 77.41 | 79.47 | 78.00 | |||||
*Market average exchange rate | ||||||||||||
Period-end | ||||||||||||
Actual | Actual | Actual | ||||||||||
FY2019 | FY2020 | FY2021 | ||||||||||
31 Dec. | 31 Mar. | 30 Jun. | 30 Sep. | 31 Dec. | 31 Mar. | 30 Jun. | 30 Sep. | 31 Dec. | ||||
CHF | 112.31 | 112.49 | 113.07 | 114.92 | 117.10 | 117.14 | ||||||
EUR | 121.93 | 119.13 | 120.93 | 124.08 | 126.89 | 129.30 | ||||||
USD | 108.88 | 107.83 | 107.57 | 105.66 | 103.19 | 110.37 | ||||||
SGD | 80.72 | 75.73 | 77.18 | 77.19 | 77.98 | 81.87 |
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS) | 1 |
Reconciliation of IFRS results to Core results
(Billions of yen) | |||||||||||
FY2020 | FY2021 | ||||||||||
1-3 | 1-3 | ||||||||||
IFRS results | Intangible | Others | Core results | IFRS results | Intangible | Others | Core results | ||||
assets | assets | ||||||||||
Revenues | 179.4 | - | - | 179.4 | 168.8 | - | - | 168.8 | |||
Sales | 144.5 | - | - | 144.5 | 130.3 | - | - | 130.3 | |||
Royalties and other operating income | 34.9 | - | - | 34.9 | 38.6 | - | - | 38.6 | |||
Cost of sales | (61.3) | 0.3 | - | (61.0) | (55.3) | 0.3 | - | (55.0) | |||
Gross profit | 118.2 | 0.3 | - | 118.5 | 113.5 | 0.3 | - | 113.8 | |||
Operatingexpenses | (45.7) | 0.2 | 1.2 | (44.4) | (49.5) | 0.0 | 1.1 | (48.5) | |||
Marketing and distribution | (15.8) | - | 0.3 | (15.5) | (15.9) | - | 0.0 | (15.8) | |||
Research and development | (26.1) | 0.2 | 0.9 | (25.0) | (29.7) | 0.0 | 1.0 | (28.7) | |||
General and administration | (3.9) | - | - | (3.9) | (3.9) | - | 0.0 | (3.9) | |||
Operating profit | 72.4 | 0.5 | 1.2 | 74.1 | 64.0 | 0.3 | 1.1 | 65.4 | |||
Financing costs | (0.0) | - | - | (0.0) | (0.0) | - | - | (0.0) | |||
Other financial income (expense) | (0.6) | - | - | (0.6) | 0.3 | - | - | 0.3 | |||
Other expense | (0.5) | - | - | (0.5) | - | - | - | - | |||
Profitbefore taxes | 71.2 | 0.5 | 1.2 | 72.9 | 64.2 | 0.3 | 1.1 | 65.6 | |||
Income taxes | (19.7) | (0.1) | (0.3) | (20.2) | (16.8) | (0.1) | (0.3) | (17.2) | |||
Net income | 51.5 | 0.3 | 0.8 | 52.7 | 47.4 | 0.2 | 0.8 | 48.4 | |||
Attributable to | |||||||||||
Chugai shareholders | 51.5 | 0.3 | 0.8 | 52.7 | 47.4 | 0.2 | 0.8 | 48.4 | |||
Non-controlling interests | - | - | - | - | - | - | - | - |
Core results
Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results, and are consistent with the Core concept disclosed by Roche. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.
The table above shows the reconciliation of IFRS results into Core results. The detail is as below.
Intangible assets
Amortization (0.4 billion yen in 2020 and 0.3 billion yen in 2021)
Impairment (0.1 billion yen in 2020 and none in 2021)
Others
Restructuring expenses (1.2 billion yen in 2020 and 1.1 billion yen in 2021)
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS) | 2 | |||||||||||||||||
IFRS results (QTR) | ||||||||||||||||||
3 | 4 | 5 | 6 | (Billions of yen) | ||||||||||||||
Actual | Actual | |||||||||||||||||
FY2020 | FY2021 | |||||||||||||||||
1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change | 4-6 | Change | 7-9 | Change | 10-12 | Change | |||||||
QTR | QTR | QTR | QTR | QTR | (%) | QTR | (%) | QTR | (%) | QTR | (%) | |||||||
Revenues | 179.4 | 188.7 | 208.4 | 210.4 | 168.8 | (5.9) | ||||||||||||
Sales | 144.5 | 161.1 | 159.1 | 168.5 | 130.3 | (9.8) | ||||||||||||
Domestic | 101.9 | 102.7 | 98.6 | 105.9 | 94.9 | (6.9) | ||||||||||||
Overseas | 42.6 | 58.4 | 60.6 | 62.6 | 35.4 | (16.9) | ||||||||||||
Royalties and other operating income | 34.9 | 27.6 | 49.3 | 41.9 | 38.6 | +10.6 | ||||||||||||
Royalty and profit-sharing income | 26.4 | 27.1 | 35.6 | 40.5 | 36.6 | +38.6 | ||||||||||||
Other operating income | 8.5 | 0.5 | 13.6 | 1.4 | 2.0 | (76.5) | ||||||||||||
Cost of sales | (61.3) | (70.6) | (69.4) | (72.3) | (55.3) | (9.8) | ||||||||||||
(% of Sales) | 42.4 | 43.8 | 43.6 | 42.9 | 42.4 | - | ||||||||||||
Gross profit | 118.2 | 118.1 | 139.0 | 138.2 | 113.5 | (4.0) | ||||||||||||
(% of Revenues) | 65.9 | 62.6 | 66.7 | 65.7 | 67.2 | - | ||||||||||||
Operating expenses | (45.7) | (49.9) | (52.4) | (64.2) | (49.5) | +8.3 | ||||||||||||
(% of Revenues) | 25.5 | 26.4 | 25.1 | 30.5 | 29.3 | - | ||||||||||||
Marketing and distribution | (15.8) | (17.0) | (17.0) | (22.8) | (15.9) | +0.6 | ||||||||||||
(% of Revenues) | 8.8 | 9.0 | 8.2 | 10.8 | 9.4 | - | ||||||||||||
Research and development | (26.1) | (28.8) | (30.1) | (32.8) | (29.7) | +13.8 | ||||||||||||
(% of Revenues) | 14.5 | 15.3 | 14.4 | 15.6 | 17.6 | - | ||||||||||||
General and administration | (3.9) | (4.1) | (5.2) | (8.6) | (3.9) | 0.0 | ||||||||||||
(% of Revenues) | 2.2 | 2.2 | 2.5 | 4.1 | 2.3 | - | ||||||||||||
Operating profit | 72.4 | 68.2 | 86.7 | 73.9 | 64.0 | (11.6) | ||||||||||||
(% of Revenues) | 40.4 | 36.1 | 41.6 | 35.1 | 37.9 | - | ||||||||||||
Financing costs | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | 0.0 | ||||||||||||
Other financial income (expense) | (0.6) | 0.5 | (0.8) | (0.5) | 0.3 | - | ||||||||||||
Other expense | (0.5) | (0.3) | (0.3) | (0.4) | - | - | ||||||||||||
Profit before taxes | 71.2 | 68.4 | 85.6 | 73.1 | 64.2 | (9.8) | ||||||||||||
(% of Revenues) | 39.7 | 36.2 | 41.1 | 34.7 | 38.0 | - | ||||||||||||
Income taxes | (19.7) | (17.6) | (25.4) | (20.7) | (16.8) | (14.7) | ||||||||||||
Net income | 51.5 | 50.8 | 60.1 | 52.3 | 47.4 | (8.0) | ||||||||||||
(% of Revenues) | 28.7 | 26.9 | 28.8 | 24.9 | 28.1 | - | ||||||||||||
Attributable to | ||||||||||||||||||
Chugai shareholders | 51.5 | 50.8 | 60.1 | 52.3 | 47.4 | (8.0) | ||||||||||||
Non-controlling interests | - | - | - | - | - | - | ||||||||||||
Earnings per share | ||||||||||||||||||
Basic (yen) | 31.37 | 30.89 | 36.58 | 31.82 | 28.84 | (8.1) | ||||||||||||
Diluted (yen) | 31.33 | 30.85 | 36.55 | 31.80 | 28.82 | (8.0) |
Other financial income (expense) includes net amount of FX related gains/losses.
Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. "Earnings per share (Basic)" and "Earnings per share (Diluted)" presents the amount after the stock split.
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS) | 3 | |||||||||||||||||
IFRS results (YTD) | ||||||||||||||||||
2 | 3 | (Billions of yen) | ||||||||||||||||
Actual | Actual | Actual | ||||||||||||||||
FY2019 | FY2020 | FY2021 | ||||||||||||||||
1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change | 1-6 | Change | 1-9 | Change | 1-12 | Change | ||||||
YTD | YTD | YTD | YTD | YTD | YTD | (%) | YTD | (%) | YTD | (%) | YTD | (%) | ||||||
Revenues | 686.2 | 179.4 | 368.1 | 576.5 | 786.9 | 168.8 | (5.9) | |||||||||||
Sales | 588.9 | 144.5 | 305.7 | 464.8 | 633.3 | 130.3 | (9.8) | |||||||||||
Domestic | 437.6 | 101.9 | 204.6 | 303.2 | 409.1 | 94.9 | (6.9) | |||||||||||
Overseas | 151.3 | 42.6 | 101.0 | 161.6 | 224.2 | 35.4 | (16.9) | |||||||||||
Royalties and other operating income | 97.3 | 34.9 | 62.5 | 111.7 | 153.6 | 38.6 | +10.6 | |||||||||||
Royalty and profit-sharing income | 76.5 | 26.4 | 53.5 | 89.1 | 129.6 | 36.6 | +38.6 | |||||||||||
Other operating income | 20.8 | 8.5 | 9.0 | 22.6 | 24.1 | 2.0 | (76.5) | |||||||||||
Cost of sales | (266.1) | (61.3) | (131.8) | (201.2) | (273.5) | (55.3) | (9.8) | |||||||||||
(% of Sales) | 45.2 | 42.4 | 43.1 | 43.3 | 43.2 | 42.4 | - | |||||||||||
Gross profit | 420.1 | 118.2 | 236.3 | 375.3 | 513.5 | 113.5 | (4.0) | |||||||||||
(% of Revenues) | 61.2 | 65.9 | 64.2 | 65.1 | 65.3 | 67.2 | - | |||||||||||
Operating expenses | (209.5) | (45.7) | (95.7) | (148.0) | (212.3) | (49.5) | +8.3 | |||||||||||
(% of Revenues) | 30.5 | 25.5 | 26.0 | 25.7 | 27.0 | 29.3 | - | |||||||||||
Marketing and distribution | (77.2) | (15.8) | (32.8) | (49.8) | (72.6) | (15.9) | +0.6 | |||||||||||
(% of Revenues) | 11.3 | 8.8 | 8.9 | 8.6 | 9.2 | 9.4 | - | |||||||||||
Research and development | (107.9) | (26.1) | (54.9) | (85.0) | (117.9) | (29.7) | +13.8 | |||||||||||
(% of Revenues) | 15.7 | 14.5 | 14.9 | 14.7 | 15.0 | 17.6 | - | |||||||||||
General and administration | (24.4) | (3.9) | (8.0) | (13.2) | (21.8) | (3.9) | 0.0 | |||||||||||
(% of Revenues) | 3.6 | 2.2 | 2.2 | 2.3 | 2.8 | 2.3 | - | |||||||||||
Operating profit | 210.6 | 72.4 | 140.6 | 227.3 | 301.2 | 64.0 | (11.6) | |||||||||||
(% of Revenues) | 30.7 | 40.4 | 38.2 | 39.4 | 38.3 | 37.9 | - | |||||||||||
Financing costs | (0.1) | (0.0) | (0.0) | (0.0) | (0.1) | (0.0) | 0.0 | |||||||||||
Other financial income (expense) | 0.5 | (0.6) | (0.2) | (1.0) | (1.5) | 0.3 | - | |||||||||||
Other expense | (3.1) | (0.5) | (0.9) | (1.1) | (1.5) | - | - | |||||||||||
Profit before taxes | 207.9 | 71.2 | 139.6 | 225.1 | 298.2 | 64.2 | (9.8) | |||||||||||
(% of Revenues) | 30.3 | 39.7 | 37.9 | 39.0 | 37.9 | 38.0 | - | |||||||||||
Income taxes | (50.3) | (19.7) | (37.3) | (62.7) | (83.5) | (16.8) | (14.7) | |||||||||||
Net income | 157.6 | 51.5 | 102.3 | 162.4 | 214.7 | 47.4 | (8.0) | |||||||||||
(% of Revenues) | 23.0 | 28.7 | 27.8 | 28.2 | 27.3 | 28.1 | - | |||||||||||
Attributable to | ||||||||||||||||||
Chugai shareholders | 157.6 | 51.5 | 102.3 | 162.4 | 214.7 | 47.4 | (8.0) | |||||||||||
Non-controlling interests | - | - | - | - | - | - | - | |||||||||||
Earnings per share | ||||||||||||||||||
Basic (yen) | 95.95 | 31.37 | 62.26 | 98.84 | 130.66 | 28.84 | (8.1) | |||||||||||
Diluted (yen) | 95.81 | 31.33 | 62.18 | 98.74 | 130.53 | 28.82 | (8.0) |
Other financial income (expense) includes net amount of FX related gains/losses.
Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. "Earnings per share (Basic)" and "Earnings per share (Diluted)" presents the amount after the stock split.
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS) | 4 | |||||||||||||||||
Core results (QTR) | ||||||||||||||||||
3 | 4 | 5 | 6 | (Billions of yen) | ||||||||||||||
Actual | Actual | |||||||||||||||||
FY2020 | FY2021 | |||||||||||||||||
1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change | 4-6 | Change | 7-9 | Change | 10-12 | Change | |||||||
QTR | QTR | QTR | QTR | QTR | (%) | QTR | (%) | QTR | (%) | QTR | (%) | |||||||
Revenues | 179.4 | 188.7 | 208.4 | 210.4 | 168.8 | (5.9) | ||||||||||||
Sales | 144.5 | 161.1 | 159.1 | 168.5 | 130.3 | (9.8) | ||||||||||||
Domestic | 101.9 | 102.7 | 98.6 | 105.9 | 94.9 | (6.9) | ||||||||||||
Overseas | 42.6 | 58.4 | 60.6 | 62.6 | 35.4 | (16.9) | ||||||||||||
Royalties and other operating income | 34.9 | 27.6 | 49.3 | 41.9 | 38.6 | +10.6 | ||||||||||||
Royalty and profit-sharing income | 26.4 | 27.1 | 35.6 | 40.5 | 36.6 | +38.6 | ||||||||||||
Other operating income | 8.5 | 0.5 | 13.6 | 1.4 | 2.0 | (76.5) | ||||||||||||
Cost of sales | (61.0) | (70.3) | (69.1) | (72.0) | (55.0) | (9.8) | ||||||||||||
(% of Sales) | 42.2 | 43.6 | 43.4 | 42.7 | 42.2 | - | ||||||||||||
Gross profit | 118.5 | 118.4 | 139.3 | 138.5 | 113.8 | (4.0) | ||||||||||||
(% of Revenues) | 66.1 | 62.7 | 66.8 | 65.8 | 67.4 | - | ||||||||||||
Operating expenses | (44.4) | (48.8) | (51.2) | (62.4) | (48.5) | +9.2 | ||||||||||||
(% of Revenues) | 24.7 | 25.9 | 24.6 | 29.7 | 28.7 | - | ||||||||||||
Marketing and distribution | (15.5) | (16.8) | (16.7) | (22.5) | (15.8) | +1.9 | ||||||||||||
(% of Revenues) | 8.6 | 8.9 | 8.0 | 10.7 | 9.4 | - | ||||||||||||
Research and development | (25.0) | (27.9) | (29.3) | (31.3) | (28.7) | +14.8 | ||||||||||||
(% of Revenues) | 13.9 | 14.8 | 14.1 | 14.9 | 17.0 | - | ||||||||||||
General and administration | (3.9) | (4.1) | (5.2) | (8.6) | (3.9) | 0.0 | ||||||||||||
(% of Revenues) | 2.2 | 2.2 | 2.5 | 4.1 | 2.3 | - | ||||||||||||
Operating profit | 74.1 | 69.7 | 88.2 | 76.1 | 65.4 | (11.7) | ||||||||||||
(% of Revenues) | 41.3 | 36.9 | 42.3 | 36.2 | 38.7 | - | ||||||||||||
Financing costs | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | 0.0 | ||||||||||||
Other financial income (expense) | (0.6) | 0.5 | (0.8) | (0.5) | 0.3 | - | ||||||||||||
Other expense | (0.5) | (0.3) | (0.3) | (0.4) | - | - | ||||||||||||
Profit before taxes | 72.9 | 69.8 | 87.0 | 75.2 | 65.6 | (10.0) | ||||||||||||
(% of Revenues) | 40.6 | 37.0 | 41.7 | 35.7 | 38.9 | - | ||||||||||||
Income taxes | (20.2) | (18.0) | (25.9) | (21.4) | (17.2) | (14.9) | ||||||||||||
Net income | 52.7 | 51.8 | 61.2 | 53.8 | 48.4 | (8.2) | ||||||||||||
(% of Revenues) | 29.4 | 27.5 | 29.4 | 25.6 | 28.7 | - | ||||||||||||
Attributable to | ||||||||||||||||||
Chugai shareholders | 52.7 | 51.8 | 61.2 | 53.8 | 48.4 | (8.2) | ||||||||||||
Non-controlling interests | - | - | - | - | - | - | ||||||||||||
Core earnings per share (diluted) (yen) | 32.04 | 31.47 | 37.17 | 32.71 | 29.42 | (8.2) |
Please see page 1 "Reconciliation of IFRS results to Core results" for the detail of the adjustments.
Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share. Other financial income (expense) includes net amount of FX related gains/losses.
Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. Core EPS presents the amount after the stock split.
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS) | 5 | ||||||||||||||||||||
Core results (YTD) | |||||||||||||||||||||
6 | 6 | 6 | 6 | 6 | (Billions of yen) | ||||||||||||||||
Forecast | |||||||||||||||||||||
Actual | Actual | Actual | (Feb 4th | ||||||||||||||||||
announced) | |||||||||||||||||||||
FY2019 | FY2020 | FY2021 | FY2021 | ||||||||||||||||||
1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change | 1-6 | Change | 1-9 | Change | 1-12 | Change | 1-12 | Change | |||||||
YTD | YTD | YTD | YTD | YTD | YTD | (%) | YTD | (%) | YTD | (%) | YTD | (%) | YTD | (%) | |||||||
Revenues | 686.2 | 179.4 | 368.1 | 576.5 | 786.9 | 168.8 | (5.9) | 800.0 | +1.7 | ||||||||||||
Sales | 588.9 | 144.5 | 305.7 | 464.8 | 633.3 | 130.3 | (9.8) | 631.0 | (0.4) | ||||||||||||
Domestic | 437.6 | 101.9 | 204.6 | 303.2 | 409.1 | 94.9 | (6.9) | 393.7 | (3.8) | ||||||||||||
Overseas | 151.3 | 42.6 | 101.0 | 161.6 | 224.2 | 35.4 | (16.9) | 237.3 | +5.8 | ||||||||||||
Royalties and other operating income | 97.3 | 34.9 | 62.5 | 111.7 | 153.6 | 38.6 | +10.6 | 169.0 | +10.0 | ||||||||||||
Royalty and profit-sharing income | 76.5 | 26.4 | 53.5 | 89.1 | 129.6 | 36.6 | +38.6 | 163.0 | +25.8 | ||||||||||||
Other operating income | 20.8 | 8.5 | 9.0 | 22.6 | 24.1 | 2.0 | (76.5) | 6.0 | (75.1) | ||||||||||||
Cost of sales | (265.1) | (61.0) | (131.2) | (200.3) | (272.3) | (55.0) | (9.8) | (252.5) | (7.3) | ||||||||||||
(% of Sales) | 45.0 | 42.2 | 42.9 | 43.1 | 43.0 | 42.2 | - | 40.0 | - | ||||||||||||
Gross profit | 421.1 | 118.5 | 236.9 | 376.2 | 514.7 | 113.8 | (4.0) | 547.5 | +6.4 | ||||||||||||
(% of Revenues) | 61.4 | 66.1 | 64.4 | 65.3 | 65.4 | 67.4 | - | 68.4 | - | ||||||||||||
Operating expenses | (196.2) | (44.4) | (93.2) | (144.3) | (206.7) | (48.5) | +9.2 | (227.5) | +10.1 | ||||||||||||
(% of Revenues) | 28.6 | 24.7 | 25.3 | 25.0 | 26.3 | 28.7 | - | 28.4 | - | ||||||||||||
Marketing and distribution | (73.5) | (15.5) | (32.3) | (49.0) | (71.5) | (15.8) | +1.9 | ||||||||||||||
(% of Revenues) | 10.7 | 8.6 | 8.8 | 8.5 | 9.1 | 9.4 | - | ||||||||||||||
Research and development | (102.1) | (25.0) | (52.9) | (82.2) | (113.5) | (28.7) | +14.8 | (131.5) | +15.9 | ||||||||||||
(% of Revenues) | 14.9 | 13.9 | 14.4 | 14.3 | 14.4 | 17.0 | - | 16.4 | - | ||||||||||||
General and administration | (20.6) | (3.9) | (8.0) | (13.1) | (21.7) | (3.9) | 0.0 | ||||||||||||||
(% of Revenues) | 3.0 | 2.2 | 2.2 | 2.3 | 2.8 | 2.3 | - | ||||||||||||||
Operating profit | 224.9 | 74.1 | 143.7 | 231.9 | 307.9 | 65.4 | (11.7) | 320.0 | +3.9 | ||||||||||||
(% of Revenues) | 32.8 | 41.3 | 39.0 | 40.2 | 39.1 | 38.7 | - | 40.0 | - | ||||||||||||
Financing costs | (0.1) | (0.0) | (0.0) | (0.0) | (0.1) | (0.0) | 0.0 | ||||||||||||||
Other financial income (expense) | 0.5 | (0.6) | (0.2) | (1.0) | (1.5) | 0.3 | - | ||||||||||||||
Other expense | (3.1) | (0.5) | (0.9) | (1.1) | (1.5) | - | - | ||||||||||||||
Profit before taxes | 222.2 | 72.9 | 142.7 | 229.7 | 304.9 | 65.6 | (10.0) | ||||||||||||||
(% of Revenues) | 32.4 | 40.6 | 38.8 | 39.8 | 38.7 | 38.9 | - | ||||||||||||||
Income taxes | (54.6) | (20.2) | (38.2) | (64.1) | (85.5) | (17.2) | (14.9) | ||||||||||||||
Net income | 167.6 | 52.7 | 104.5 | 165.6 | 219.4 | 48.4 | (8.2) | 232.0 | +5.7 | ||||||||||||
(% of Revenues) | 24.4 | 29.4 | 28.4 | 28.7 | 27.9 | 28.7 | - | 29.0 | - | ||||||||||||
Attributable to | |||||||||||||||||||||
Chugai shareholders | 167.6 | 52.7 | 104.5 | 165.6 | 219.4 | 48.4 | (8.2) | ||||||||||||||
Non-controlling interests | - | - | - | - | - | - | - | ||||||||||||||
Weighted average number of shares in | |||||||||||||||||||||
issue used to calculate diluted earnings per | 1,645 | 1,645 | 1,645 | 1,645 | 1,645 | 1,645 | 0.0 | ||||||||||||||
share (Millions of shares) | |||||||||||||||||||||
Core earnings per share (diluted) (yen) | 101.93 | 32.04 | 63.51 | 100.68 | 133.39 | 29.42 | (8.2) | 141.00 | +5.7 | ||||||||||||
Core payout ratio (%) | 45.8 | 41.2 | 42.6 | - | |||||||||||||||||
Dividend per share (Full year) (yen) | 140 | - | 60 | - | |||||||||||||||||
Dividend per share (Year end) (yen) | 92 | 30 | 30 | - | |||||||||||||||||
Dividend per share (Half year) (yen) | 48 | 75 | 30 | - |
Please see page 1 "Reconciliation of IFRS results to Core results" for the detail of the adjustments.
Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share. Other financial income (expense) includes net amount of FX related gains/losses.
Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock. Core EPS presents the amount after the stock split. Weighted average number of shares in issue used to calculate diluted earnings per share presents the amount after the stock split.
The dividend for the fiscal year ended December 31, 2019 and the second quarter of the fiscal year 2020 presents the amount prior to the stock split.
The annual dividend per share for the fiscal year ended December 31, 2020 is not stated because the amounts cannot be simply combined due to the implementation of the stock split. The annual dividend per share is ¥165 when calculated based on the assumption of no stock split, and ¥55 when calculated with the stock split taken into account.
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS) | 6 | ||||||||||||||||||
Statements of revenues (QTR) | |||||||||||||||||||
Actual | Actual | ||||||||||||||||||
FY2020 | FY2021 | ||||||||||||||||||
1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change | 4-6 | Change | 7-9 | Change | 10-12 | Change | ||||||||
QTR | QTR | QTR | QTR | QTR | (%) | QTR | (%) | QTR | (%) | QTR | (%) | ||||||||
Sales | 144.5 | 161.1 | 159.1 | 168.5 | 130.3 | (9.8) | |||||||||||||
Domestic | 101.9 | 102.7 | 98.6 | 105.9 | 94.9 | (6.9) | |||||||||||||
Oncology | 55.3 | 58.1 | 56.0 | 62.9 | 57.9 | +4.7 | |||||||||||||
Avastin | 20.4 | 20.4 | 19.7 | 21.1 | 18.8 | (7.8) | |||||||||||||
Tecentriq | 7.8 | 8.8 | 8.9 | 12.0 | 14.1 | +80.8 | |||||||||||||
Perjeta | 8.3 | 8.4 | 8.1 | 8.7 | 7.4 | (10.8) | |||||||||||||
Alecensa | 5.6 | 6.6 | 6.4 | 7.3 | 6.0 | +7.1 | |||||||||||||
Kadcyla | 2.1 | 2.5 | 2.6 | 3.1 | 3.2 | +52.4 | |||||||||||||
Herceptin | 4.5 | 4.1 | 3.7 | 3.6 | 2.6 | (42.2) | |||||||||||||
Gazyva | 1.0 | 1.0 | 1.1 | 1.3 | 1.0 | 0.0 | |||||||||||||
Rituxan | 1.9 | 1.8 | 1.8 | 1.8 | 1.2 | (36.8) | |||||||||||||
Xeloda | 1.1 | 0.9 | 0.8 | 0.8 | 0.6 | (45.5) | |||||||||||||
Rozlytrek | 0.0 | 0.1 | 0.1 | 0.2 | 0.1 | - | |||||||||||||
Foundation Medicine | 0.6 | 0.6 | 0.8 | 0.9 | 1.0 | +66.7 | |||||||||||||
Other products | 2.0 | 2.8 | 2.1 | 2.1 | 1.8 | (10.0) | |||||||||||||
Primary | 46.6 | 44.6 | 42.6 | 43.0 | 36.9 | (20.8) | |||||||||||||
Hemlibra | 7.9 | 8.2 | 8.4 | 9.5 | 8.8 | +11.4 | |||||||||||||
Actemra | 9.5 | 9.7 | 9.4 | 10.7 | 9.2 | (3.2) | |||||||||||||
Edirol | 8.8 | 9.5 | 5.9 | 3.6 | 2.9 | (67.0) | |||||||||||||
Mircera | 4.2 | 4.3 | 4.5 | 4.6 | 3.4 | (19.0) | |||||||||||||
Bonviva | 2.1 | 2.1 | 2.3 | 2.4 | 2.0 | (4.8) | |||||||||||||
CellCept | 2.2 | 2.3 | 2.2 | 2.4 | 2.0 | (9.1) | |||||||||||||
Oxarol | 1.4 | 1.6 | 1.6 | 1.7 | 1.4 | 0.0 | |||||||||||||
Enspryng | - | - | 0.3 | 1.0 | 1.4 | - | |||||||||||||
Tamiflu(Ordinary use) | 0.6 | 0.0 | 0.0 | 0.2 | (0.1) | - | |||||||||||||
Tamiflu(Govt. stockpiles etc.) | 2.6 | - | 0.3 | 0.7 | 1.2 | (53.8) | |||||||||||||
Other products | 7.2 | 7.0 | 7.7 | 6.0 | 4.7 | (34.7) | |||||||||||||
Overseas | 42.6 | 58.4 | 60.6 | 62.6 | 35.4 | (16.9) | |||||||||||||
Hemlibra | 8.6 | 7.9 | 5.1 | 4.5 | 8.5 | (1.2) | |||||||||||||
To Roche | 8.2 | 7.5 | 4.7 | 4.2 | 8.0 | (2.4) | |||||||||||||
Actemra | 24.1 | 36.5 | 37.0 | 36.8 | 17.4 | (27.8) | |||||||||||||
To Roche | 23.5 | 35.9 | 36.5 | 36.0 | 16.9 | (28.1) | |||||||||||||
Alecensa | 6.2 | 10.7 | 13.9 | 13.6 | 6.0 | (3.2) | |||||||||||||
To Roche | 5.9 | 10.3 | 13.6 | 13.2 | 5.6 | (5.1) | |||||||||||||
Enspryng | 0.1 | 0.3 | 1.1 | 4.0 | - | - | |||||||||||||
To Roche | 0.1 | 0.3 | 1.1 | 4.0 | - | - | |||||||||||||
Neutrogin | 2.5 | 2.0 | 2.3 | 2.3 | 2.2 | (12.0) | |||||||||||||
Other products | 1.1 | 1.1 | 1.1 | 1.4 | 1.2 | +9.1 | |||||||||||||
Royalties and other operating income | 34.9 | 27.6 | 49.3 | 41.9 | 38.6 | +10.6 | |||||||||||||
Royalty and profit-sharing income | 26.4 | 27.1 | 35.6 | 40.5 | 36.6 | +38.6 | |||||||||||||
Other operating income | 8.5 | 0.5 | 13.6 | 1.4 | 2.0 | (76.5) | |||||||||||||
Revenues | 179.4 | 188.7 | 208.4 | 210.4 | 168.8 | (5.9) | |||||||||||||
Domestic | 109.5 | 102.7 | 100.6 | 106.2 | 95.3 | (13.0) | |||||||||||||
Overseas | 69.9 | 86.0 | 107.8 | 104.3 | 73.6 | +5.3 |
From the 1st Quarter of FY2021, sales for Foundation Medicine is included "Oncology", instead of "Others" until FY2020.
Also sales for products included "Bone and Joint", "Renal Diseases", "Others" until FY2020, are included "Primary" from the 1st Quarter of FY2021.
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS) | 7 | |||||||||||||||||||||
Statements of revenues (YTD) | ||||||||||||||||||||||
(Billions of yen) | ||||||||||||||||||||||
Actual | Actual | Forecast | ||||||||||||||||||||
Actual | (Feb 4th | |||||||||||||||||||||
announced) | ||||||||||||||||||||||
FY2019 | FY2020 | FY2021 | FY2021 | |||||||||||||||||||
1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change | 1-6 | Change | 1-9 | Change | 1-12 | Change | 1-12 | Change | ||||||||
YTD | YTD | YTD | YTD | YTD | YTD | (%) | YTD | (%) | YTD | (%) | YTD | (%) | YTD | (%) | ||||||||
Sales | 588.9 | 144.5 | 305.7 | 464.8 | 633.3 | 130.3 | (9.8) | 631.0 | (0.4) | |||||||||||||
Domestic | 437.6 | 101.9 | 204.6 | 303.2 | 409.1 | 94.9 | (6.9) | 393.7 | (3.8) | |||||||||||||
Oncology | 240.9 | 55.3 | 113.4 | 169.4 | 232.3 | 57.9 | +4.7 | 226.7 | (2.4) | |||||||||||||
Avastin | 95.6 | 20.4 | 40.7 | 60.4 | 81.5 | 18.8 | (7.8) | 60.5 | (25.8) | |||||||||||||
Tecentriq | 20.6 | 7.8 | 16.6 | 25.5 | 37.5 | 14.1 | +80.8 | 49.2 | +31.2 | |||||||||||||
Perjeta | 30.7 | 8.3 | 16.7 | 24.8 | 33.5 | 7.4 | (10.8) | 31.8 | (5.1) | |||||||||||||
Alecensa | 23.0 | 5.6 | 12.3 | 18.7 | 26.0 | 6.0 | +7.1 | 27.0 | +3.8 | |||||||||||||
Kadcyla | 9.0 | 2.1 | 4.6 | 7.1 | 10.2 | 3.2 | +52.4 | 13.3 | +30.4 | |||||||||||||
Herceptin | 26.7 | 4.5 | 8.6 | 12.3 | 15.9 | 2.6 | (42.2) | 10.9 | (31.4) | |||||||||||||
Gazyva | 3.6 | 1.0 | 2.1 | 3.2 | 4.6 | 1.0 | 0.0 | 5.7 | +23.9 | |||||||||||||
Rituxan | 11.9 | 1.9 | 3.7 | 5.5 | 7.2 | 1.2 | (36.8) | 5.2 | (27.8) | |||||||||||||
Xeloda | 8.0 | 1.1 | 2.0 | 2.8 | 3.6 | 0.6 | (45.5) | 2.7 | (25.0) | |||||||||||||
Rozlytrek | 0.0 | 0.0 | 0.1 | 0.2 | 0.4 | 0.1 | - | 0.9 | +125.0 | |||||||||||||
Foundation Medicine | 0.4 | 0.6 | 1.2 | 2.0 | 2.8 | 1.0 | +66.7 | 7.2 | +157.1 | |||||||||||||
Other products | 11.3 | 2.0 | 4.9 | 6.9 | 9.1 | 1.8 | (10.0) | 12.3 | +35.2 | |||||||||||||
Primary | 196.6 | 46.6 | 91.2 | 133.8 | 176.8 | 36.9 | (20.8) | 167.0 | (5.5) | |||||||||||||
Hemlibra | 25.2 | 7.9 | 16.1 | 24.6 | 34.1 | 8.8 | +11.4 | 51.7 | +51.6 | |||||||||||||
Actemra | 41.8 | 9.5 | 19.1 | 28.6 | 39.3 | 9.2 | (3.2) | 38.5 | (2.0) | |||||||||||||
Edirol | 36.7 | 8.8 | 18.3 | 24.2 | 27.8 | 2.9 | (67.0) | 17.3 | (37.8) | |||||||||||||
Mircera | 22.2 | 4.2 | 8.5 | 12.9 | 17.5 | 3.4 | (19.0) | 11.7 | (33.1) | |||||||||||||
Bonviva | 9.7 | 2.1 | 4.2 | 6.5 | 8.9 | 2.0 | (4.8) | 8.5 | (4.5) | |||||||||||||
CellCept | 9.3 | 2.2 | 4.5 | 6.7 | 9.1 | 2.0 | (9.1) | 8.3 | (8.8) | |||||||||||||
Oxarol | 6.9 | 1.4 | 3.1 | 4.7 | 6.4 | 1.4 | 0.0 | 5.5 | (14.1) | |||||||||||||
Enspryng | - | - | - | 0.3 | 1.3 | 1.4 | - | 4.0 | +207.7 | |||||||||||||
Tamiflu(Ordinary use) | 7.4 | 0.6 | 0.7 | 0.7 | 0.8 | (0.1) | - | 0.8 | 0.0 | |||||||||||||
Tamiflu(Govt. stockpiles etc.) | 3.2 | 2.6 | 2.6 | 3.0 | 3.7 | 1.2 | (53.8) | 1.2 | (67.6) | |||||||||||||
Other products | 34.3 | 7.2 | 14.2 | 21.9 | 27.9 | 4.7 | (34.7) | 19.6 | (29.7) | |||||||||||||
Overseas | 151.3 | 42.6 | 101.0 | 161.6 | 224.2 | 35.4 | (16.9) | 237.3 | +5.8 | |||||||||||||
Hemlibra | 3.6 | 8.6 | 16.4 | 21.5 | 26.1 | 8.5 | (1.2) | 89.7 | +243.7 | |||||||||||||
To Roche | 3.3 | 8.2 | 15.7 | 20.4 | 24.6 | 8.0 | (2.4) | 88.0 | +257.7 | |||||||||||||
Actemra | 88.3 | 24.1 | 60.6 | 97.6 | 134.4 | 17.4 | (27.8) | 85.3 | (36.5) | |||||||||||||
To Roche | 86.5 | 23.5 | 59.4 | 96.0 | 132.0 | 16.9 | (28.1) | 83.0 | (37.1) | |||||||||||||
Alecensa | 45.3 | 6.2 | 16.8 | 30.7 | 44.3 | 6.0 | (3.2) | 44.2 | (0.2) | |||||||||||||
To Roche | 44.6 | 5.9 | 16.2 | 29.8 | 43.0 | 5.6 | (5.1) | 42.5 | (1.2) | |||||||||||||
Enspryng | - | 0.1 | 0.4 | 1.6 | 5.6 | - | - | 3.9 | (30.4) | |||||||||||||
To Roche | - | 0.1 | 0.4 | 1.6 | 5.6 | - | - | 3.9 | (30.4) | |||||||||||||
Neutrogin | 9.9 | 2.5 | 4.5 | 6.8 | 9.0 | 2.2 | (12.0) | 8.7 | (3.3) | |||||||||||||
Other products | 4.2 | 1.1 | 2.2 | 3.4 | 4.8 | 1.2 | +9.1 | 5.4 | +12.5 | |||||||||||||
Royalties and other operating income | 97.3 | 34.9 | 62.5 | 111.7 | 153.6 | 38.6 | +10.6 | 169.0 | +10.0 | |||||||||||||
Royalty and profit-sharing income | 76.5 | 26.4 | 53.5 | 89.1 | 129.6 | 36.6 | +38.6 | 163.0 | +25.8 | |||||||||||||
Other operating income | 20.8 | 8.5 | 9.0 | 22.6 | 24.1 | 2.0 | (76.5) | 6.0 | (75.1) | |||||||||||||
Revenues | 686.2 | 179.4 | 368.1 | 576.5 | 786.9 | 168.8 | (5.9) | 800.0 | +1.7 | |||||||||||||
Domestic | 444.0 | 109.5 | 212.2 | 312.8 | 419.0 | 95.3 | (13.0) | 394.2 | (5.9) | |||||||||||||
Overseas | 242.2 | 69.9 | 155.9 | 263.7 | 368.0 | 73.6 | +5.3 | 405.8 | +10.3 |
From the 1st Quarter of FY2021, sales for Foundation Medicine is included "Oncology", instead of "Others" until FY2020.
Also sales for products included "Bone and Joint", "Renal Diseases", "Others" until FY2020, are included "Primary" from the 1st Quarter of FY2021.
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS) | 8 | |||||||||||||||||
Financial position | ||||||||||||||||||
(Billions of yen) | ||||||||||||||||||
Actual | Actual | Actual | ||||||||||||||||
FY2019 | FY2020 | FY2021 | ||||||||||||||||
Dec. 31 | Mar. 31 | Jun. 30 | Sep. 30 | Dec. 31 | Mar. 31 | vs. Mar. 31, 2020 | vs. Dec. 31, 2020 | Jun. 30 | vs. Jun. 30, 2020 | vs. Dec. 31, 2020 | Sep. 30 | vs. Sep. 30, 2020 | vs. Dec. 31, 2020 | Dec. 31 | vs. Dec. 31, 2020 | |||
Trade accounts receivable | 139.6 | 150.1 | 169.2 | 172.6 | 195.6 | 138.4 | (11.7) | (57.2) | ||||||||||
Inventories | 168.1 | 174.4 | 172.0 | 179.6 | 183.9 | 184.7 | 10.3 | 0.8 | ||||||||||
Trade accounts payable | (47.7) | (51.3) | (44.7) | (45.2) | (58.3) | (42.1) | 9.2 | 16.2 | ||||||||||
Other net working capital | (22.9) | (21.5) | 8.5 | (18.4) | (21.2) | 0.3 | 21.8 | 21.5 | ||||||||||
Net working capital | 237.2 | 251.6 | 305.0 | 288.5 | 300.0 | 281.3 | 29.7 | (18.7) | ||||||||||
Property, plant and equipment | 255.6 | 277.4 | 275.3 | 288.3 | 289.2 | 291.4 | 14.0 | 2.2 | ||||||||||
Right-of-use assets | 9.7 | 8.4 | 7.7 | 9.0 | 8.3 | 7.4 | (1.0) | (0.9) | ||||||||||
Intangible assets | 23.5 | 23.8 | 24.0 | 23.8 | 23.9 | 26.0 | 2.2 | 2.1 | ||||||||||
Other long-term assets - net | 21.0 | 24.9 | 24.4 | 24.1 | 24.6 | 25.5 | 0.6 | 0.9 | ||||||||||
Long-term net operating assets | 309.8 | 334.5 | 331.3 | 345.1 | 346.0 | 350.3 | 15.8 | 4.3 | ||||||||||
Net operating assets | 547.0 | 586.1 | 636.3 | 633.6 | 646.0 | 631.6 | 45.5 | (14.4) | ||||||||||
Debt | - | - | - | - | - | - | - | - | ||||||||||
Marketable securities | 129.1 | 134.0 | 94.1 | 136.1 | 166.3 | 181.3 | 47.3 | 15.0 | ||||||||||
Cash and cash equivalents | 203.9 | 138.7 | 196.6 | 182.7 | 212.3 | 162.0 | 23.3 | (50.3) | ||||||||||
Net cash | 333.1 | 272.7 | 290.7 | 318.8 | 378.6 | 343.4 | 70.7 | (35.2) | ||||||||||
Other non-operating assets - net | (26.1) | (4.7) | (21.1) | (27.2) | (44.6) | 7.7 | 12.4 | 52.3 | ||||||||||
Net non-operating assets | 307.0 | 268.0 | 269.6 | 291.7 | 334.0 | 351.0 | 83.0 | 17.0 | ||||||||||
Total net assets | 854.0 | 854.1 | 905.9 | 925.3 | 980.0 | 982.6 | 128.5 | 2.6 | ||||||||||
Total net assets | ||||||||||||||||||
Total assets | 1,058.9 | 1,045.6 | 1,072.1 | 1,136.1 | 1,235.5 | 1,144.6 | 99.0 | (90.9) | ||||||||||
Total liabilities | (204.9) | (191.5) | (166.2) | (210.8) | (255.5) | (162.0) | 29.5 | 93.5 | ||||||||||
Attributable to | ||||||||||||||||||
Chugai shareholders | 854.0 | 854.1 | 905.9 | 925.3 | 980.0 | 982.6 | 128.5 | 2.6 | ||||||||||
Non-controlling interests | - | - | - | - | - | - | - | - |
Trade accounts receivable: trade receivable and notes receivable
Trade accounts payable: trade payable and notes payable
Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc.
Other long-termassets-net:long-term prepaid expenses, long-term provisions etc.
Other non-operatingassets-net: deferred income tax assets, current income tax liabilities etc.
Net operating assets (NOA) and Net assets:
The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, "Presentation of Financial Statements." On the other hand, Net operating assets (NOA) and Net assets are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from Net operating assets (NOA) and Net assets of IFRS have been excluded, as the Core results concept only applies to the income statement.
Net operating assets (NOA):
Net operating assets allow for an assessment of the Group's operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital, long-term net operating assets that includes property, plant and equipment, right-of-use assets, intangible assets etc. minus provisions.
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS) | 9 | ||||||||||||
Cash flows | |||||||||||||
(Billions of yen) | |||||||||||||
Actual | Actual | Actual | |||||||||||
FY2019 | FY2020 | FY2021 | |||||||||||
1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | |||||
YTD | YTD | YTD | YTD | YTD | YTD | YTD | YTD | YTD | |||||
Operating profit - IFRS basis | 210.6 | 72.4 | 140.6 | 227.3 | 301.2 | 64.0 | |||||||
Depreciation and impairment of property, plant and equipment | 19.0 | 5.2 | 10.5 | 16.1 | 22.3 | 5.3 | |||||||
Depreciation and impairment of right-of-use assets | 6.0 | 1.5 | 2.8 | 4.2 | 5.5 | 1.3 | |||||||
Amortization and impairment of intangible assets | 5.3 | 0.9 | 1.6 | 2.3 | 3.6 | 0.7 | |||||||
Other cash adjustment on operating profit | 4.3 | 1.1 | 2.0 | 3.1 | 2.9 | 0.9 | |||||||
Operating profit, net of operating cash adjustments | 245.2 | 81.0 | 157.6 | 253.0 | 335.5 | 72.2 | |||||||
(Increase) decrease in trade accounts receivable | 11.1 | (10.5) | (29.5) | (32.9) | (55.9) | 57.4 | |||||||
(Increase) decrease in inventories | (9.0) | (6.8) | 3.6 | 6.4 | 3.3 | (1.0) | |||||||
Increase (decrease) in trade accounts payable | 11.8 | 3.7 | (3.0) | (2.5) | 10.5 | (16.5) | |||||||
Change in other net working capital etc. | (7.7) | (21.2) | (32.4) | (27.1) | (22.3) | 0.3 | |||||||
Total (increase) decrease in net working capital etc. | 6.2 | (34.8) | (61.4) | (56.1) | (64.4) | 40.2 | |||||||
Investment in property, plant and equipment | (53.0) | (11.1) | (40.6) | (47.3) | (57.0) | (28.9) | |||||||
Lease liabilities paid | (8.9) | (2.1) | (4.2) | (6.3) | (8.4) | (2.2) | |||||||
Investment in intangible assets | (8.2) | (1.2) | (2.3) | (3.1) | (4.3) | (2.9) | |||||||
Operating free cash flows | 181.4 | 31.8 | 49.0 | 140.3 | 201.2 | 78.3 | |||||||
as % of revenues | 26.4% | 17.7% | 13.3% | 24.3% | 25.6% | 46.4% | |||||||
Treasury activities (interest income/expenses, foreign exchange gains/losses etc.) | (0.9) | 0.6 | 2.2 | 3.7 | 2.5 | (2.5) | |||||||
Settlement for transfer pricing taxation | (3.1) | (0.5) | (0.9) | (1.1) | (1.5) | - | |||||||
Tax paid | (34.8) | (41.0) | (41.9) | (66.4) | (66.8) | (63.3) | |||||||
Free cash flows | 142.6 | (9.1) | 8.4 | 76.4 | 135.4 | 12.4 | |||||||
Dividends paid | (56.4) | (50.1) | (50.4) | (91.2) | (91.4) | (49.0) | |||||||
Transaction in own equity instruments | 0.7 | 0.3 | 0.3 | 0.4 | 0.4 | 0.2 | |||||||
Purchase of non-controlling interests | (2.3) | - | - | - | - | - | |||||||
Net effect of currency translation on net cash | (0.8) | (1.4) | (0.8) | 0.2 | 1.2 | 1.2 | |||||||
Net change in net cash | 83.9 | (60.4) | (42.4) | (14.3) | 45.5 | (35.2) |
Other cash adjustment on operating profit: adjustments for all non-cash income and expense items other than amortization expenses and impairment included in operating profit (such as loss on inventory differences, reserve for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in reserves) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) including proceeds from the sales of assets and reserve payments.
Operating free cash flow (Operating FCF): pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to "operating profit, net of operating cash adjustments," which shows the company's cash generation ability from operating activities.
Free cash flow (FCF): the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF.
Net change in net cash: dividends paid, increases and decreases in marketable securities and interest-bearing debt、changes in equity are included.
The concepts of operating profit, operating FCF and Net operating assets (NOA) presented in the previous page are mutually consistent. Free cash flow (FCF):
The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, "Statement of Cash Flows." FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results concept only applies to the income statement.
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2021(IFRS) | 10 |
Key Performance indicators
Actual | Actual | Actual | Forecast | ||||||||
(Feb 4th | |||||||||||
announced) | |||||||||||
2019 | 2020 | 2021 | 2021 | ||||||||
1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-12 | ||
Units | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Dec. 31 | |
Total indicator | |||||||||||
Core return on invested capital (Core ROIC) | % | 31.9 | 9.5 | 17.8 | 28.4 | 37.3 | 7.5 | ||||
Return on invested capital (ROIC) | % | 30.1 | 9.3 | 17.5 | 27.9 | 36.5 | 7.4 | ||||
Ratio of profit to total assets (ROA) | % | 15.8 | 4.9 | 9.6 | 14.8 | 18.7 | 4.0 | ||||
Ratio of equity attributable to | |||||||||||
% | 80.6 | 81.7 | 84.5 | 81.4 | 79.3 | 85.8 | |||||
Chugai shareholders | |||||||||||
Ratio of equity attributable to | % | 521.2 | 654.7 | 883.9 | 682.2 | 732.2 | 644.8 | ||||
Chugai shareholders (stock price base) | |||||||||||
Price book value ratio(PBR) | times | 6.5 | 8.0 | 10.5 | 8.4 | 9.2 | 7.5 | ||||
Ratio of net income to equity attributable to | % | 19.6 | 6.0 | 11.6 | 18.3 | 23.4 | 4.8 | ||||
Chugai shareholders (ROE) | |||||||||||
Margin indicator | |||||||||||
ROS | % | 32.8 | 41.3 | 39.0 | 40.2 | 39.1 | 38.7 | 40.0 | |||
COS ratio(vs. Prod. sales) | % | 45.0 | 42.2 | 42.9 | 43.1 | 43.0 | 42.2 | 40.0 | |||
M&D cost ratio | % | 10.7 | 8.6 | 8.8 | 8.5 | 9.1 | 9.4 | ||||
R&D cost ratio | % | 14.9 | 13.9 | 14.4 | 14.3 | 14.4 | 17.0 | 16.4 | |||
G&A cost ratio | % | 3.0 | 2.2 | 2.2 | 2.3 | 2.8 | 2.3 | ||||
Turn over indicator | |||||||||||
Total asset turnorver | % | 68.9 | 17.1 | 34.5 | 52.5 | 68.6 | 14.2 | ||||
Working capital turnover | % | 128.7 | 31.7 | 62.2 | 97.7 | 131.9 | 26.4 | ||||
Inventory turnover | Months | 7.6 | 8.5 | 7.8 | 8.0 | 8.1 | 10.0 | ||||
Receivables turnover | Months | 2.8 | 3.1 | 3.3 | 3.3 | 3.7 | 3.2 | ||||
Payables turnover | Months | 2.2 | 2.5 | 2.0 | 2.0 | 2.6 | 2.3 | ||||
Fixed asset turnover | % | 250.0 | 60.0 | 123.6 | 189.1 | 257.9 | 52.2 | ||||
PP&E turnover | % | 287.3 | 67.3 | 138.7 | 212.0 | 288.9 | 58.2 | ||||
intangible assets turnover | % | 2,968.0 | 757.7 | 1,548.1 | 2,436.2 | 3,319.0 | 676.6 | ||||
Dividend / per stock indicator | |||||||||||
Dividends per share (Half year) | Yen | 48 | 75 | 30 | |||||||
Dividends per share (Year end) | Yen | 92 | 30 | 30 | |||||||
Dividends per share (Full year) | Yen | 140 | - | 60 | |||||||
Core earnings per share (diluted) | Yen | 101.93 | 32.04 | 63.51 | 100.68 | 133.39 | 29.42 | 141.00 | |||
Core payout ratio (%) | % | 45.8 | 41.2 | 42.6 | |||||||
Equity per share attributable | Yen | 519.91 | 519.90 | 551.13 | 562.88 | 596.16 | 597.67 | ||||
to Chugai shareholders (BPS) | |||||||||||
Ratio of dividends to equity attributable to | % | 9.5 | 9.9 | ||||||||
Chugai shareholders (DOE) | |||||||||||
Cashflow indicator | |||||||||||
Cash conversion cycle(CCC) | Months | 8.3 | 9.1 | 9.1 | 9.4 | 9.2 | 10.9 | ||||
Net cash turnover period | Months | 5.8 | 4.6 | 4.7 | 5.0 | 5.8 | 6.1 | ||||
Number of employees | 7,394 | 7,400 | 7,536 | 7,559 | 7,555 | 7,490 | |||||
Investment on property, plant and equipment | Billions of yen | 54.0 | 27.3 | 38.7 | 67.9 | 75.2 | 7.4 | 79.5 | |||
Depreciation | Billions of yen | 17.8 | 5.2 | 10.5 | 16.1 | 22.0 | 5.3 | 21.0 | |||
Investment on intangible assets | Billions of yen | 6.1 | 1.1 | 2.1 | 2.5 | 3.9 | 2.9 | ||||
Amortization | Billions of yen | 2.6 | 0.7 | 1.5 | 2.2 | 2.9 | 0.7 |
Core ROIC:Core net operting profit after taxes / Net operating assets (Core ROIC is calculated by using Core Income taxes)
ROIC: Net operating profit after taxes / Net operating assets (Net operating profit after taxes = Operating profit - income taxes)
ROA: Net income / total assets, ROE: Net income attributable for Chugai shareholders / Equity attributable to Chugai shareholders
Total asset turnorver: Revenues / Total asset, CCC:[Trade accounts receivable/Sales+(Inventories - Trade accounts payable)/Cost of sales]* passed months Net cash turnover period:Net cash/Revenue* passed months
Core ROIC, ROIC, ROA, ROE, total asset turnover, working capital turnover, fixed asset turnover, PP&E turnover, and intangible assets turnover are not annualized The Adjusted figures are used for calculating average NOA for Core ROIC and ROIC
Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. ("Chugai") implemented a three-for-one stock split of its common stock.
The dividend for the fiscal year ended December 31, 2019 and the second quarter of the fiscal year 2020 presents the amount prior to the stock split.
The annual dividend per share for the fiscal year ended December 31, 2020 is not stated because the amounts cannot be simply combined due to the implementation of the stock split. The annual dividend per share is ¥165 when calculated based on the assumption of no stock split, and ¥55 when calculated with the stock split taken into account.
Core EPS and BPS presents the amount after the stock split.
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 11
Development pipeline (as of April 22, 2021)
Origin | Indication | Stage | Generic name | ||
Development code | Overseas name | Product name | Mode of Action | ||
# Additional indication | (Date) | ||||
(Collaborator) | Dosage form | ||||
Oncology | |||||
RG7596 | Roche/Seattle Genetics | Relapsed or refractory diffuse large B-cell | Approved | polatuzumab vedotin | Anti-CD79bantibody-drug conjugate |
Polivy | lymphoma (DLBCL) | (21/03) | Polivy | ||
Injection | |||||
DLBCL | Phase III | ||||
# | |||||
RG7446 | Roche | Non-small cell lung cancer (NSCLC) | Phase III | atezolizumab | Engineered anti-PD-L1 monoclonal antibody |
Tecentriq | (adjuvant) | Tecentriq | |||
# | Injection | ||||
NSCLC (neoadjuvant) | Phase III | ||||
# | |||||
NSCLC (stage III) | Phase III | ||||
# | (in combination with | ||||
RG6058) | |||||
Urothelial carcinoma | Phase III | ||||
# | |||||
Renal cell carcinoma (adjuvant) | Phase III | ||||
# | |||||
Roche | Renal cell carcinoma (2nd Line) | Phase III | |||
Tecentriq | # | (in combination with | |||
(Takeda) | cabozantinib) | ||||
Roche | Early breast cancer | Phase III | |||
Tecentriq | # | ||||
Ovarian cancer | Phase III | ||||
# | (in combination with | ||||
RG435) | |||||
Hepatocellular carcinoma (HCC) (adjuvant) | Phase III | ||||
# | (in combination with | ||||
RG435) | |||||
HCC (intermediate stage) | Phase III | ||||
# | (in combination with | ||||
RG435) | |||||
Head and neck carcinoma (adjuvant) | Phase III | ||||
# |
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 12
Origin | Indication | Stage | Generic name | ||
Development code | Overseas name | Product name | Mode of Action | ||
# Additional indication | (Date) | ||||
(Collaborator) | Dosage form | ||||
Esophageal cancer | Phase III | ||||
# | (in combination with | ||||
RG6058) | |||||
Pancreatic adenocarcinoma | Phase I | ||||
# | Morpheus platform | ||||
(in combination with | |||||
RG1569 or RG6058) | |||||
RG435 | Roche | HCC (adjuvant) | Phase III | bevacizumab | Anti-VEGF (Vascular Endothelial Growth |
Avastin | # | (in combination with | Avastin | Factor) humanized monoclonal antibody | |
RG7446) | Injection | ||||
HCC (intermediate stage) | Phase III | ||||
# | (in combination with | ||||
RG7446) | |||||
Small cell lung cancer (SCLC) | Phase III | ||||
# | (in combination with | ||||
RG7446) | |||||
RG7440 | Roche/Array BioPharma | Breast cancer | Phase III | ipatasertib | AKT inhibitor |
Oral | |||||
Prostate cancer | Phase III | ||||
RG6264 | Roche | Breast cancer | Phase III | trastuzumab/pertuzumab | Anti-HER2 humanized monoclonal antibody/ |
Phesgo | (Fixed-dose combination, subcutaneous | HER2 dimerization inhibitory humanized | |||
injection) | Injection | monoclonal antibody | |||
AF802 / RG7853 | In-house | NSCLC (adjuvant) | Phase III | alectinib | ALK inhibitor |
Alecensa | # | Alecensa | |||
(Roche) | Oral | ||||
RG6058 | Roche | SCLC | Phase III | tiragolumab | Anti-TIGIT human monoclonal antibody |
(in combination with | |||||
RG7446) | Injection | ||||
NSCLC | Phase III | ||||
(in combination with | |||||
RG7446) | |||||
NSCLC (stage III) | Phase III | ||||
(in combination with | |||||
RG7446) |
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 13
Origin | Indication | Stage | Generic name | ||||
Development code | Overseas name | Product name | Mode of Action | ||||
# Additional indication | (Date) | ||||||
(Collaborator) | Dosage form | ||||||
Esophageal cancer | Phase III | ||||||
(in combination with | |||||||
RG7446) | |||||||
RG6171 | Roche | Breast cancer | Phase III | giredestrant | SERD (Selective Estrogen Receptor Degrader) | ||
Oral | |||||||
OBP-301 | Oncolys BioPharma | Esophageal cancer | Phase II | Oncolytic type 5 adenovirus | |||
Injection | |||||||
HCC | Phase I | ||||||
(in combination with | |||||||
RG7446 and RG435) | |||||||
GC33 | In-house | HCC | Phase I | codrituzumab | Anti-Glypican-3 | humanized | monoclonal |
antibody | |||||||
Injection | |||||||
ERY974 | In-house | Solid tumors | Phase I | Anti-Glypican-3/CD3 bispecific antibody | |||
Injection | |||||||
RG7421 | Roche/Exelixis | Solid tumors | Phase I | cobimetinib | MEK inhibitor | ||
Cotellic | |||||||
Oral | |||||||
RG7802 | Roche | Solid tumors | Phase I | cibisatamab | Anti-CEA/CD3 bispecific antibody | ||
Injection | |||||||
RG7828 | Roche | Hematologic tumors | Phase I | mosunetuzumab | Anti-CD20/CD3 bispecific antibody | ||
Injection | |||||||
RG6026 | Roche | Hematologic tumors | Phase I | glofitamab | Anti-CD20/CD3 bispecific antibody | ||
Injection | |||||||
AMY109 | In-house | Solid tumors | Phase I | ‒ | |||
Injection | |||||||
STA551 | In-house | Solid tumors | Phase I | Anti-CD137 agonistic Switch antibody | |||
Injection |
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 14
Origin | Indication | Stage | Generic name | |||
Development code | Overseas name | Product name | Mode of Action | |||
# Additional indication | (Date) | |||||
(Collaborator) | Dosage form | |||||
SPYK04 | In-house | Solid tumors | Phase I | ‒ | ||
Oral | ||||||
RG6194 | Roche | Solid tumors | Phase I | Anti-HER2/CD3 bispecific antibody | ||
Injection | ||||||
Bone and Joint Diseases | ||||||
ED-71 | In-house | Osteoporosis | Approved | eldecalcitol | Activated vitamin D3 agent | |
(20/12) | Edirol | |||||
China | Oral | |||||
NRD101 | In-house | Knee osteoarthritis / Shoulder periarthritis | Phase III | purified | sodium | Sodium hyaluronate |
(China) | hyaluronate | |||||
Suvenyl | ||||||
Injection | ||||||
Renal Diseases | ||||||
EOS789 | In-house | Hyperphosphatemia | Phase I | NaPi-IIb,PiT-1,PiT-2 inhibitor | ||
Oral | ||||||
Autoimmune Diseases | ||||||
RG7880 | Roche | Inflammatory bowel disease | Phase I | efmarodocokin alfa | Human IL-22 fusion protein | |
Injection | ||||||
Neurology | ||||||
SA237 / RG6168 | In-house | Neuromyelitis optica spectrum disorder | Filed | satralizumab | pH-dependent binding humanized anti-IL-6 | |
Enspryng | (NMOSD) | (19/08) | Enspryng | receptor monoclonal antibody | ||
(Roche) | EU | Injection | ||||
RG7916 | Roche/PTC Therapeutics | Spinal muscular atrophy (SMA) | Filed | risdiplam | SMN2 splicing modifier | |
Evrysdi | (20/10) | |||||
Oral | ||||||
RG1450 | Roche/MorphoSys | Alzheimer's disease | Phase III | gantenerumab | Anti-amyloid-beta human monoclonal antibody | |
Injection | ||||||
RG6042 | Roche/Ionis | Huntington's disease | Phase III | tominersen | Antisense oligonucleotide targeting HTT mRNA | |
Pharmaceuticals | ||||||
Injection |
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 15
Origin | Indication | Stage | Generic name | ||
Development code | Overseas name | Product name | Mode of Action | ||
# Additional indication | (Date) | ||||
(Collaborator) | Dosage form | ||||
RG7906 | Roche | Schizophrenia | Phase II | ralmitaront | Partial TAAR1 agonist |
Oral | |||||
RG7935 | Roche/Prothena | Parkinson's disease | Phase I | prasinezumab | Anti-α-synuclein monoclonal antibody |
Injection | |||||
GYM329 / RG6237 | In-house | Neuromuscular disease | Phase I | Anti-latent myostatin sweeping antibody | |
(Roche) | Injection | ||||
RG6100 | Roche/AC Immune | Alzheimer's disease | Phase I | semorinemab | Anti-tau humanized monoclonal antibody |
injection | |||||
Other diseases | |||||
MRA / RG1569 | In-house | COVID-19 pneumonia | Phase III* | tocilizumab | Humanized anti-humanIL-6 receptor |
Actemra/RoActemra (EU) | # | (Japan) | Actemra | monoclonal | |
Injection | antibody | ||||
RG7716 | Roche | Diabetic macular edema | Phase III | faricimab | Anti-VEGF/Ang2 bispecific antibody |
Neovascular age related macular | Phase III | Injection | |||
degeneration (nAMD) | |||||
Retinal vein occlusion | Phase III | ||||
ACE910 / RG6013 | In-house | Acquired hemophilia A | Phase III | emicizumab | Anti-coagulation factor IXa/X humanized |
Hemlibra | # | (Japan) | Hemlibra | bispecific monoclonal antibody | |
Injection | |||||
SKY59 / RG6107 | In-house | Paroxysmal nocturnal hemoglobinuria | Phase III | crovalimab | Anti-C5 recycling antibody |
(PNH) | |||||
(Roche) | Injection | ||||
NXT007 | In-house | Hemophilia A | Phase l/II | Anti-coagulation factor IXa/X bispecific | |
antibody | |||||
Injection | |||||
PCO371 | In-house | Hypoparathyroidism | Phase I | PTH1 receptor agonist | |
Oral | |||||
AMY109 | In-house | Endometriosis | Phase l | ‒ | |
Injection |
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 16
Origin | Indication | Stage | Generic name | ||
Development code | Overseas name | Product name | Mode of Action | ||
# Additional indication | (Date) | ||||
(Collaborator) | Dosage form | ||||
RG6413/RG6412 | Roche/Regeneron | COVID-19 | Phase l | casirivimab/imdevimab | SARS-CoV-2 Neutralizing antibody |
Pharmaceuticals | cocktail | ||||
Injection |
In principle, completion of first dose is regarded as the start of clinical studies in each phase. * Roche is conducting global Phase III studies of Actemra/RoActemra against COVID-19 pneumonia separately.
Changes from the last announcement on February 4, 2021
Oncology | |
- RG7596 | Filed (Relapsed or refractory diffuse large B-cell lymphoma) → Approved |
- RG7446 | Phase III (HCC (intermediate stage) / in combination with RG435: development started) |
- RG435 | Phase III (HCC (intermediate stage) / in combination with RG7446: development started) |
Other diseases | |
- RG7716 | Phase III (Retinal vein occlusion: development started) |
- RG6413/RG6412 | Phase I (COVID-19: development started) |
R&D Activities
For the changes during the FY2021 (January 1 - March 31), please refer to page 4 of "CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the first quarter of the fiscal year 2021)."
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 17
Major Chugai originated developments licensed out to 3rd party excluding Roche
Development code | Generic name | Licensee | |||
Indication | Stage | Product name | Mode of Action | ||
in Chugai | (granted right ) | ||||
Dosage form | |||||
CIM331 | Atopic dermatitis | Filled | nemolizumab | Maruho | Anti-IL-31 receptor A humanized |
(20/Q3) | (rights for development and marketing in the | monoclonal antibody | |||
Japan | Injection | skin disease area for the Japanese market) | |||
Phase III | Galderma | ||||
(global) | (exclusive global license for the | ||||
development and marketing excluding | |||||
Japan and Taiwan) | |||||
Prurigo nodularis | Phase III | Galderma | |||
(global) | (exclusive global license for the | ||||
development and marketing excluding | |||||
Japan and Taiwan) | |||||
Phase II/III | Maruho | ||||
(Japan) | (rights for development and marketing in | ||||
the skin disease area for the Japanese | |||||
market) | |||||
OWL833 | Type 2 diabetes | Phase I | Eli Lilly and Company | Oral non-peptidicGLP-1 receptor | |
(worldwide development and | agonist | ||||
Oral | commercialization rights) |
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 18
Major clinical trials in oncology field
Treatment | Expected Indication | Study design | Study name | Stage | Planned filing year | |
NSCLC [1st line] | PD-L1 positive: Tecentriq ± RG6058 | SKYSCRAPER-01 | Phase III | 2023 | ||
NSCLC [stage III] | Tecentriq + RG6058 vs. durvalumab | SKYSCRAPER-03 | Phase III | 2024 and beyond | ||
NSCLC [2nd line] | Tecentriq + cabozantinib vs. docetaxel | CONTACT-01 | Phase III | 2023 | ||
NSCLC (neoadjuvant) | Chemo ± Tecentriq | IMpower030 | Phase III | 2023 | ||
NSCLC (adjuvant) | Tecentriq vs. best supportive care | IMpower010 | Phase III | 2021 | ||
SCLC | Tecentriq + chemo ± Avastin | BEAT-SC | Phase III | 2023 | ||
Tecentriq + chemo ± RG6058 | SKYSCRAPER-02 | Phase III | 2022 | |||
Urothelial carcinoma (UC) | Tecentriq ± chemo vs. chemo | IMvigor130 | Phase III | 2022 | ||
RG7446 | Renal cell carcinoma (adjuvant) | Tecentriq | IMmotion010 | Phase III | 2022 | |
Renal cell carcinoma [2nd line] | cabozantinib ± Tecentriq | CONTACT-03 | Phase III | 2023d | ||
(Tecentriq) | ||||||
Early breast cancer | TNBC (adjuvant): paclitaxel ± Tecentriq | IMpassion030 | Phase III | 2024 and beyond | ||
TNBC (neoadjuvant): nab-paclitaxel ± Tecentriq | IMpassion031 | Phase III | ||||
Ovarian cancer | carboplatin + paclitaxel + Avastin ± Tecentriq | IMagyn050 | Phase III | 2022 | ||
HCC (adjuvant) | Tecentriq + Avastin vs. active surveillance | IMbrave050 | Phase III | 2022 | ||
HCC (intermediate stage) | Tecentriq + Avastin + TACE vs. TACE | TALENTACE | Phase III | 2024 and beyond | ||
Head and neck carcinoma (adjuvant) | Tecentriq | IMvoke010 | Phase III | 2022 | ||
Esophageal cancer | Tecentriq + RG6058 vs. Tecentriq vs. placebo | SKYSCRAPER-07 | Phase III | 2024 and beyond | ||
Pancreatic adenocarcinoma [1st line] | Tecentriq + Actemra vs. gemcitabine + nab-paclitaxel | Morpheus-PC | Phase I | ⁻ | ||
Tecentriq + RG6058 vs. gemcitabine + nab-paclitaxel | ⁻ | |||||
RG7440 | Prostate cancer | castration-resistant: abiraterone ± RG7440 | IPATential150 | Phase III | 2022 | |
(ipatasertib) | Breast cancer | fulvestrant + palbociclib ± RG7440 | IPATunity150 | Phase Ib/III | 2024 and beyond | |
RG7596 | DLBCL | Rituxan + Chemo ± RG7596 | POLARIX | Phase III | 2021 | |
(polatuzumab vedotin) | ||||||
RG6264 | Breast cancer | RG6264 (SC) + chemo vs. Herceptin (IV) + Perjeta (IV) + chemo | FeDeriCa | Phase III | 2021 | |
AF802 (Alecensa) | NSCLC (adjuvant) | ALK fusion-positive: Alecensa vs. chemo | ALINA | Phase III | 2023 | |
RG6171 / SERD | Breast cancer | HR positive: RG6171 + palbocicilib ± Letrozole | - | Phase III | 2024 and beyond | |
OBP-301 | Esophageal cancer | OBP-301 + radiotherapy | - | Phase II* | 2024 and beyond |
TNBC: triple negative breast cancer, HR: hormone receptor, TACE: transarterial chemoembolization, *: domestic
Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2021 (IFRS) 19 | ||
FoudationOne CDx Cancer Genomic Profile: companion diagnostic indications (as of April 22, 2021) | ||
Alterations | Cancer type | Relevant drugs |
Activated EGFR gene alterations | NSCLC | afatinib dimaleate, erlotinib hydrochloride, gefitinib, osimertinib mesylate |
EGFR exon 20 T790M alterations | osimertinib mesylate | |
ALK fusion genes | alectinib hydrochloride, crizotinib, ceritinib | |
ROS1 fusion genes | entrectinib | |
MET exon 14 skipping alterations | capmatinib hydrochloride hydrate | |
BRAF V600E and V600K alterations | Malignant melanoma | dabrafenib mesylate, trametinib dimethyl sulfoxide, vemurafenib |
ERBB2 copy number alterations (HER2 gene | Breast cancer | trastuzumab (genetical recombination) |
amplification positive) | ||
KRAS/NRAS wild-type | Colorectal cancer | cetuximab (genetical recombination), panitumumab (genetical recombination) |
Microsatellite Instability-High | nivolumab (genetical recombination) | |
Microsatellite Instability-High | Solid tumors | pembrolizumab (genetical recombination) |
NTRK1/2/3 fusion gene | entrectinib, larotrectinib sulfate | |
BRCA1/2 alterations | Ovarian cancer | olaparib |
BRCA1/2 alterations | Prostate cancer | olaparib |
FGFR2 fusion genes | Biliary Tract Cancer | pemigatinib |
* Underlined are the companion diagnostic features and relevant drugs currently | under application for regulatory approval | |
FoudationOne Liquid CDx Cancer Genomic Profile: companion diagnostic indications (as of April 22 2021) | ||
Alterations | Cancer type | Relevant drugs |
Activated EGFR gene alterations | NSCLC | afatinib dimaleate, erlotinib hydrochloride, gefitinib, osimertinib mesylate |
EGFR exon 20 T790M alterations | osimertinib mesylate | |
ALK fusion genes | alectinib hydrochloride, crizotinib, ceritinib | |
ROS1 fusion genes | entrectinib | |
NTRK1/2/3 fusion gene | Solid tumors | entrectinib |
Attachments
- Original document
- Permalink
Disclaimer
Chugai Pharmaceutical Co. Ltd. published this content on 22 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 April 2021 08:03:04 UTC.